Not available in the U.S.
Imrecoxib
What it isModerately selective COX-2 inhibitor NSAID.
Why this oneApproved in China for osteoarthritis, designed for less COX-1-related GI toxicity than nonselective NSAIDs while aiming for a milder cardiovascular profile than highly selective coxibs.
What limits itShares NSAID-class cardiovascular thrombotic and GI risks, is metabolized by CYP2C9 and CYP3A4, and is not FDA-approved.
⚠ BOXED WARNINGS
- Cardiovascular thrombotic events
- Gastrointestinal bleeding, ulceration and perforation
Classes and tags
Clinical profile
Mechanism of action: Imrecoxib ballicule
